23:21 , Aug 23, 2019 |  BC Extra  |  Preclinical News

Aug. 23 Preclinical Quick Takes: Mission Bio launches new feature in single-cell analysis platform; plus CRISPR-triggered hydrogel cargo release and more

Mission Bio expands single-cell analysis platform Mission Bio Inc. (South San Francisco, Calif.) launched Copy Number Analysis, a new feature integrated into its Tapestri Platform, to enable simultaneous measurement of copy number variants along with...
22:31 , Aug 14, 2019 |  BC Innovations  |  Distillery Therapeutics

Antihelminthic compound bithionol could treat MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus The antihelminthic bithionol could be repurposed to treat methicillin-resistant S. aureus (MRSA) infections. In bacterial growth assays, bithionol reduced growth of three MRSA strains and a vancomycin-resistant S. aureus...
23:20 , Jul 26, 2019 |  BC Extra  |  Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
21:18 , Jul 12, 2019 |  BC Extra  |  Politics & Policy

Senate Democrats push to empower HHS to negotiate Medicare drug prices

Democratic senators are pressing Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) to give HHS power to negotiate Medicare drug prices. In a July 11 letter to the Senate Finance Committee's chairman and ranking member,...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
06:08 , May 20, 2019 |  BioCentury  |  Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...
22:43 , Mar 6, 2019 |  BC Extra  |  Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

UCB Ventures hired Alicia Irurzun-Lafitte as a partner. She was a principal at M Ventures, the corporate venture fund of Merck KGaA (Xetra:MRK). GlycoMimetics Inc. (NASDAQ:GLYC) said Chairman Jim Barrett will retire from the board....
21:01 , Feb 8, 2019 |  BC Extra  |  Politics & Policy

Democrats reintroduce Medicare price negotiation bill

Democrats have reintroduced in both houses of Congress a Medicare drug price negotiation bill, at least the third proposed fix of the 2019 term. The Medicare Negotiation and Competitive Licensing Act, reintroduced by Rep. Lloyd...
15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
20:33 , Feb 5, 2019 |  BC Extra  |  Company News

FDA psychiatry product division director joins Allergan

Following a 12-year tenure as director of FDA’s Division of Psychiatry Products, Mitchell Mathis has joined Allergan plc (NYSE:AGN) as CMO for CNS products. Mathis left FDA on Jan. 19 and joined Allergan later in...